In fiscal 2025, which ended Nov 30, 2025, Cryo-Cell International, Inc. reported revenue of $31.6 million, down 1.3% from the year before. It recorded a net loss of $2.4 million. Operating income came to $482,394, an operating margin of 1.5%. Diluted earnings per share were -$0.30. Over the twelve months ended Aug 31, 2026, revenue was $31.1 million and the net loss was $1.9 million. Across the 10 fiscal years shown, revenue grew from $23.1 million in fiscal 2016 to $31.6 million in fiscal 2025, about 3.5% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Aug 31, 2026
|
FY 2025
Nov 30, 2025
|
FY 2024
Nov 30, 2024
|
FY 2023
Nov 30, 2023
|
FY 2022
Nov 30, 2022
|
FY 2021
Nov 30, 2021
|
FY 2020
Nov 30, 2020
|
FY 2019
Nov 30, 2019
|
FY 2018
Nov 30, 2018
|
FY 2017
Nov 30, 2017
|
FY 2016
Nov 30, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
31
-2.0%
|
32
-1.3%
|
32
+2.0%
|
31
+3.3%
|
30
+5.0%
|
29
-7.3%
|
31
-2.1%
|
32
+8.9%
|
29
+15.1%
|
25
+9.8%
|
23
+9.7%
|
| Cost of revenue |
7
-8.2%
|
7
-7.2%
|
8
-5.3%
|
8
-4.6%
|
9
-2.2%
|
9
-6.9%
|
10
-3.8%
|
10
+17.5%
|
9
|
—
|
—
|
| Gross profit |
24
-0.1%
|
24
+0.6%
|
24
+4.7%
|
23
+6.5%
|
22
+8.3%
|
20
-7.4%
|
21
-1.3%
|
22
+5.3%
|
21
|
—
|
—
|
| Research and development |
0
-49.0%
|
0
-69.7%
|
1
+6.1%
|
1
+204.4%
|
0
+671.6%
|
0
+109.1%
|
0
-20.9%
|
0
-67.2%
|
0
+123.1%
|
0
-22.5%
|
0
+16.0%
|
| Selling, general and administrative |
19
+0.4%
|
18
-1.6%
|
19
+7.9%
|
17
+10.2%
|
16
+6.6%
|
15
+2.2%
|
14
-4.0%
|
15
-4.7%
|
16
+16.0%
|
13
-8.4%
|
15
+18.8%
|
| Operating income |
0
-95.6%
|
0
-86.1%
|
3
+128.3%
|
-12
-405.7%
|
4
+0.2%
|
4
-47.6%
|
8
+51.3%
|
5
-2.4%
|
5
+3.7%
|
5
+1054.6%
|
0
-85.2%
|
| Other income (expense) |
-2
+27.0%
|
-3
-317.0%
|
-1
+36.2%
|
-1
-50.3%
|
-1
+49.9%
|
-1
+46.3%
|
-3
-56.9%
|
-2
-6.3%
|
-2
-13.7%
|
-1
+52.6%
|
-3
-48.3%
|
| Pretax income |
-2
-231.4%
|
-2
-183.3%
|
3
+121.0%
|
-13
-502.7%
|
3
+27.1%
|
3
-48.2%
|
5
+48.6%
|
3
-6.3%
|
4
-0.2%
|
4
+246.1%
|
-2
-361.2%
|
| Income tax |
0
-98.1%
|
0
-96.2%
|
2
+162.5%
|
-4
-801.8%
|
1
+3.8%
|
1
-62.7%
|
1
+28.5%
|
1
-75.4%
|
4
+241.8%
|
1
+212.9%
|
-1
+83.8%
|
| Net income |
-2
-310.8%
|
-2
-704.2%
|
0
+104.2%
|
-10
-443.6%
|
3
+33.0%
|
2
-42.5%
|
4
+58.2%
|
2
+368.0%
|
-1
-136.9%
|
2
+275.3%
|
-1
-116.3%
|
| Basic EPS |
-0.24
-311.5%
|
-0.30
-700.0%
|
0.05
+104.4%
|
-1.14
-445.5%
|
0.33
+26.9%
|
0.26
-45.8%
|
0.48
+65.5%
|
0.29
+363.6%
|
-0.11
-133.3%
|
0.33
+306.2%
|
-0.16
-118.8%
|
| Diluted EPS |
-0.24
-316.4%
|
-0.30
-700.0%
|
0.05
+104.4%
|
-1.14
-445.5%
|
0.33
+32.0%
|
0.25
-44.4%
|
0.45
+66.7%
|
0.27
+345.5%
|
-0.11
-136.7%
|
0.30
+287.5%
|
-0.16
-119.3%
|
| Weighted average shares, basic |
8
-0.2%
|
8
-0.8%
|
8
-2.5%
|
8
-1.5%
|
8
+4.0%
|
8
+7.9%
|
8
-3.2%
|
8
+4.4%
|
7
+5.7%
|
7
-12.9%
|
8
-14.9%
|
| Weighted average shares, diluted |
8
-1.3%
|
8
-1.8%
|
8
-1.5%
|
8
-1.7%
|
8
+1.5%
|
8
+2.7%
|
8
-3.2%
|
8
+12.7%
|
7
-2.5%
|
8
-5.7%
|
8
-17.2%
|
| Other measures | |||||||||||
| Depreciation and amortization |
1
-2.0%
|
1
+42.0%
|
1
-50.4%
|
1
-6.6%
|
1
+44.2%
|
1
+179.1%
|
0
-7.2%
|
0
+122.6%
|
0
+37.0%
|
0
-14.9%
|
0
+67.9%
|
| EBITDA |
1
-78.2%
|
1
-64.8%
|
4
+138.3%
|
-11
-297.4%
|
6
+9.2%
|
5
-37.0%
|
8
+47.0%
|
5
+1.8%
|
5
+4.5%
|
5
+773.4%
|
1
-80.6%
|
| Interest coverage |
0.10x
|
0.23x
|
1.87x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Gross margin |
78.54%
|
76.63%
|
75.15%
|
73.23%
|
71.02%
|
68.88%
|
68.99%
|
68.46%
|
70.77%
|
—
|
—
|
| Operating margin |
0.61%
|
1.53%
|
10.88%
|
-39.26%
|
13.27%
|
13.91%
|
24.60%
|
15.91%
|
17.76%
|
19.72%
|
1.87%
|
| Pretax margin |
-6.13%
|
-7.40%
|
8.77%
|
-42.64%
|
10.94%
|
9.04%
|
16.18%
|
10.66%
|
12.38%
|
14.28%
|
-10.72%
|
| Profit margin |
-6.25%
|
-7.70%
|
1.26%
|
-30.38%
|
9.14%
|
7.21%
|
11.64%
|
7.20%
|
-2.93%
|
9.12%
|
-5.71%
|
| EBITDA margin |
3.73%
|
4.65%
|
13.05%
|
-34.79%
|
18.21%
|
17.51%
|
25.79%
|
17.17%
|
18.38%
|
20.24%
|
2.54%
|
| Effective tax rate |
—
|
—
|
85.66%
|
—
|
16.50%
|
20.21%
|
28.07%
|
32.45%
|
123.63%
|
36.11%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- CCEL (NYSE)
- Fiscal year ends
- November 30
- Incorporated in
- DE
- Headquarters
- Oldsmar, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 862692
- Former names
- CRYO CELL INTERNATIONAL INC (until Oct 28, 2026)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- Progyny, Inc. PGNY
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
All 15 Services-Misc Health & Allied Services, NEC companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.